MENU
+Compare
CNCR
ETF ticker: NASDAQ
AS OF
Feb 24, 10:30 AM (EDT)
Price
$12.40
Change
+$0.10 (+0.81%)
Net Assets
9.64M

CNCR stock forecast, quote, news & analysis

Category: @Health
CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CNCR with price predictions
Feb 21, 2025

CNCR saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for CNCR moved out of overbought territory on February 21, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 61 similar instances where the indicator exited the overbought zone. In of the 61 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CNCR as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CNCR moved below its 50-day moving average on February 21, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CNCR broke above its upper Bollinger Band on February 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CNCR's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CNCR just turned positive on January 22, 2025. Looking at past instances where CNCR's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNCR advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 195 cases where CNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index. The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

Market Cap

The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.93B. The market cap for tickers in the group ranges from 7.74M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is APLM at 7.74M.

High and low price notable news

The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was 19%. For the same ETF, the average monthly price growth was 57%, and the average quarterly price growth was 163%. MRUS experienced the highest price growth at 18%, while DNA experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was -43%. For the same stocks of the ETF, the average monthly volume growth was -4% and the average quarterly volume growth was 105%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 82
Price Growth Rating: 67
SMR Rating: 92
Profit Risk Rating: 92
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
CNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ETF Series Solutions615 East Michigan Street, Milwaukee, WisconsinEast Michigan
Phone
(414) 765-5586
Web
N/A